Renaissance Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Renaissance Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,503	Closed	-$1.23M	–	89
2023 Q1	$1.23M	Buy	+11,503	New	+$1.32M	0.91%	28

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Renaissance Capital's RXDX Position: Q2 2023 in Review

Renaissance Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 11,503 shares — an estimated $1.23M sold.

Renaissance Capital first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $1.23M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Renaissance Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Capital sold 11,503 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.23M.
Renaissance Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Renaissance Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $1.23M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.